Suppr超能文献

降低多发性硬化症和视神经脊髓炎谱系疾病的感染风险:巴西参考中心的方法。

Reducing infection risk in multiple sclerosis and neuromyelitis optica spectrum disorders: a Brazilian reference center's approach.

机构信息

Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Neurologia,, São Paulo SP, Brazil.

Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Divisão de Doenças Infecciosas e Parasitárias, São Paulo SP, Brazil.

出版信息

Arq Neuropsiquiatr. 2022 Oct;80(10):1057-1066. doi: 10.1055/s-0042-1754348. Epub 2022 Oct 4.

Abstract

BACKGROUND

Multiple sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are the most common autoimmune diseases of the central nervous system (CNS). They present chronic relapsing courses that demand treatment with disease-modifying drugs (DMDs) to prevent inflammatory activity. Disease-modifying drugs lead to immunomodulation or immunosuppression through diverse mechanisms (e.g., shifting lymphocyte and cytokine profile, suppressing specific lymphocyte subpopulations). Thus, patients are more prone to infectious complications and associated worsening of disease.

OBJECTIVE

To present feasible strategies for mitigating the infection risk of MS and NMOSD treated patients.

METHODS

Targeted literature review concerning the management of infection risk with an emphasis on vaccination, therapy-specific measures, and particularities of the Brazilian endemic infectious diseases' scenario.

CONCLUSION

We propose a vaccination schedule, infectious screening routine, and prophylactic measures based on the current scientific evidence. Awareness of emergent tropical diseases is necessary due to evidence of demyelinating events and possible parainfectious cases of MS and NMOSD.

摘要

背景

多发性硬化症(MS)和视神经脊髓炎谱系疾病(NMOSD)是中枢神经系统(CNS)最常见的自身免疫性疾病。它们表现为慢性复发性病程,需要使用疾病修正药物(DMD)进行治疗,以预防炎症活动。疾病修正药物通过多种机制(例如,改变淋巴细胞和细胞因子谱,抑制特定淋巴细胞亚群)实现免疫调节或免疫抑制。因此,患者更容易发生感染并发症,并导致疾病恶化。

目的

提出可行的策略来降低接受治疗的 MS 和 NMOSD 患者的感染风险。

方法

针对感染风险的管理进行目标性文献回顾,重点关注疫苗接种、针对特定疗法的措施以及巴西地方性传染病的特殊情况。

结论

我们根据现有科学证据提出了疫苗接种计划、感染筛查常规和预防措施。由于有脱髓鞘事件和 MS 和 NMOSD 可能的副感染病例的证据,因此需要了解新发热带病。

相似文献

1
Reducing infection risk in multiple sclerosis and neuromyelitis optica spectrum disorders: a Brazilian reference center's approach.
Arq Neuropsiquiatr. 2022 Oct;80(10):1057-1066. doi: 10.1055/s-0042-1754348. Epub 2022 Oct 4.
3
Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders.
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 4;7(5). doi: 10.1212/NXI.0000000000000787. Print 2020 Sep.
4
Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
Qatar Med J. 2022 Jul 7;2022(3):29. doi: 10.5339/qmj.2022.29. eCollection 2022.
6
Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
Arq Neuropsiquiatr. 2020 Jul;78(7):430-439. doi: 10.1590/0004-282X20200056. Epub 2020 Jul 1.
7
Methyl-CpG-Binding Protein 2 Emerges as a Central Player in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders.
Cell Mol Neurobiol. 2023 Nov;43(8):4071-4101. doi: 10.1007/s10571-023-01432-7. Epub 2023 Nov 13.
8
Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
Mult Scler Relat Disord. 2021 Sep;54:103104. doi: 10.1016/j.msard.2021.103104. Epub 2021 Jun 24.
10
Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review.
Mult Scler Relat Disord. 2019 Jan;27:350-363. doi: 10.1016/j.msard.2018.11.008. Epub 2018 Nov 16.

引用本文的文献

1
Could rituximab revolutionize multiple sclerosis treatment in Brazil? The missed opportunity for fewer relapses and lower costs.
Lancet Reg Health Am. 2025 Jul 1;49:101171. doi: 10.1016/j.lana.2025.101171. eCollection 2025 Sep.
2
Rewriting the prognosis of multiple sclerosis in Brazil: a 25-year perspective on evolving diagnostic criteria.
Arq Neuropsiquiatr. 2025 Jun;83(6):1-2. doi: 10.1055/s-0045-1809937. Epub 2025 Jul 2.
4
Histoplasmosis in a fingolimod-treated patient: case report and scoping review.
Rev Inst Med Trop Sao Paulo. 2024 Jul 8;66:e39. doi: 10.1590/S1678-9946202466039. eCollection 2024.

本文引用的文献

1
Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: The VELOCE study.
Neurology. 2020 Oct 6;95(14):e1999-e2008. doi: 10.1212/WNL.0000000000010380. Epub 2020 Jul 29.
2
Monoclonal Antibody Therapies for Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder.
J Clin Neurol. 2020 Jul;16(3):355-368. doi: 10.3988/jcn.2020.16.3.355.
3
Risk of MS relapse after yellow fever vaccination: A self-controlled case series.
Neurol Neuroimmunol Neuroinflamm. 2020 May 1;7(4). doi: 10.1212/NXI.0000000000000726. Print 2020 Jul.
4
Vaccines for measles, mumps, rubella, and varicella in children.
Cochrane Database Syst Rev. 2020 Apr 20;4(4):CD004407. doi: 10.1002/14651858.CD004407.pub4.
5
Childhood infections, vaccinations, and tonsillectomy and risk of first clinical diagnosis of CNS demyelination in the Ausimmune Study.
Mult Scler Relat Disord. 2020 Jul;42:102062. doi: 10.1016/j.msard.2020.102062. Epub 2020 Mar 18.
6
Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population.
Mult Scler J Exp Transl Clin. 2020 Jan 27;6(1):2055217320902488. doi: 10.1177/2055217320902488. eCollection 2020 Jan-Mar.
8
Varicella-zoster virus post-exposure management and prophylaxis: A review.
Prev Med Rep. 2019 Nov 6;16:101016. doi: 10.1016/j.pmedr.2019.101016. eCollection 2019 Dec.
9
Progressive Multifocal Leukoencephalopathy: Current Insights.
Degener Neurol Neuromuscul Dis. 2019 Dec 2;9:109-121. doi: 10.2147/DNND.S203405. eCollection 2019.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验